Skip to main content

Camiña Rodríguez, Gabriel Ig

Institutions of which they are part

Administration and Management
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Camiña Rodríguez, Gabriel Ig

Institutions of which they are part

Administration and Management
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

SGR-Cat 2021: Neuroimmunologia Clínica

IP: SGR-Cat 2021: Neuroimmunologia Clínica
Collaborators: Carlos Nos Llopis, SGR-Cat 2021: Neuroimmunologia Clínica, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, Samuel Sánchez Pous, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, SGR-Cat 2021: Neuroimmunologia Clínica, M Jesus Arevalo Navines, Edwin Roger Meza Murillo, Augusto Cesar Sao Aviles, Miguel Angel Robles Sanchez, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, Neus Mongay Ochoa, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 30/06/2025

Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

IP: Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)
Collaborators: Carlos Nos Llopis, Gabriel Ig Camiña Rodríguez, Ana Zabalza de Torres, Luciana Midaglia Fernandez
Funding agency: The Innovative Medicines Initiative
Funding: 552235
Reference: RADAR_IMI2015
Duration: 01/04/2016 - 31/03/2022

Related news

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Related professionals

Silvia Mora Marco

Silvia Mora Marco

Research assistant
Cardiovascular Diseases
Read more
Pablo Palaín Poncelas

Pablo Palaín Poncelas

Tècnic de recerca
Digital Transformation Directorate
Read more
Cristina Márquez González

Cristina Márquez González

Research technician
Stroke research
Read more
Fernando Sampedro Picon

Fernando Sampedro Picon

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.